PETRO-KING (02178) announced its performance for the year 2025. The company's owners are entitled to a profit of HKD 23.189 million, with a year-on-year turnaround from a loss to a profit.
PetroChina Lubricant Company Limited (02178) announced its financial performance for 2025, with revenue of approximately HKD 268 million, a decrease of about 8.4% year-on-year; the attributable net profit of the company's owners was HKD 23.189 million, turning from a loss to a profit year-on-year; basic earnings per share were about 1.3 HK cents.
PETRO-KING(02178) announces its performance in 2025, with revenue of approximately HKD 268 million, a decrease of about 8.4% compared to the previous year; the company's attributable profit to owners is HKD 23.189 million, turning losses into profits compared to the previous year; basic earnings per share is approximately 1.3 HK cents.
The announcement states that the decrease in revenue from the Chinese market of about HKD 6.9 million is mainly due to a reduction in production enhancement services provided in southwest China, partially offset by an increase in sales of well completion products and drilling services provided in northwest China. Revenue from overseas markets decreased by about HKD 17.6 million mainly due to several service contracts completed in 2024 with no renewals thereafter, resulting in a decrease in consulting services provided in the Middle East. In addition, comprehensive project management services provided to a client in the Middle East and drilling services provided to a client in Uzbekistan also decreased in 2025.
Related Articles
ALPHAMAB-B(09966) releases annual performance, with a net loss of 114 million RMB in the year, turning from profit to loss year-on-year.
AK MEDICAL (01789) released its annual performance with a net profit attributable to shareholders of 339 million yuan, a year-on-year increase of 23.8%.
SIMCERE PHARMA (02096) plans to acquire all equity of Shanghai Xiansheng Diagnostic Technology for 30.76 million yuan, aiming to create an open innovation exchange center.
ALPHAMAB-B(09966) releases annual performance, with a net loss of 114 million RMB in the year, turning from profit to loss year-on-year.
AK MEDICAL (01789) released its annual performance with a net profit attributable to shareholders of 339 million yuan, a year-on-year increase of 23.8%.
SIMCERE PHARMA (02096) plans to acquire all equity of Shanghai Xiansheng Diagnostic Technology for 30.76 million yuan, aiming to create an open innovation exchange center.
